0.460
-0.01 (-1.94%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Iterum Therapeutics plc | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.88 |
|
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.03% |
| 机构持股比例 | 6.41% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Apollon Financial, Llc | 30 Sep 2025 | 250,250 |
| Gen-Wealth Partners Inc | 30 Sep 2025 | 82,047 |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 23 Dec 2025 | 公告 | Iterum Therapeutics Provides Business Update |
| 17 Dec 2025 | 公告 | Iterum Therapeutics Provides Business Update |
| 05 Dec 2025 | 公告 | Iterum Therapeutics Provides Business Update |
| 24 Nov 2025 | 公告 | Iterum Therapeutics Provides Business Update |
| 14 Nov 2025 | 公告 | Iterum Therapeutics Reports Third Quarter 2025 Financial Results |
| 07 Nov 2025 | 公告 | Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合